CLChuning Liu

Chuning Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chuning Liu has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Carla J. Chibwesha

    University of North Carolina at Chapel Hill, Department of Obstetrics and Gynecology, School of Medicine, Chapel Hill, North Carolina, United States of America

    2 shared publications
  • Jessica R. Keys

    University of North Carolina at Chapel Hill, Center for AIDS Research (CFAR), School of Medicine, Chapel Hill, North Carolina, United States of America

    2 shared publications
  • Katie R. Mollan

    University of North Carolina at Chapel Hill, Center for AIDS Research (CFAR), School of Medicine, Chapel Hill, North Carolina, United States of America

    2 shared publications
  • Lisa Rahangdale

    University of North Carolina at Chapel Hill, Department of Obstetrics and Gynecology, School of Medicine, Chapel Hill, North Carolina, United States of America

    2 shared publications
  • Mark Faesen

    University of the Witwatersrand, Clinical HIV Research Unit (CHRU), Department of Internal Medicine, Faculty of Health Sciences, Johannesburg, South Africa

    2 shared publications
  • Masangu Mulongo

    University of the Witwatersrand, Clinical HIV Research Unit (CHRU), Department of Internal Medicine, Faculty of Health Sciences, Johannesburg, South Africa

    2 shared publications

Latest Publications

  • Open Access

    Efficacy of Combination Treatment for Cervical Precancer Among Women Living with HIV in South Africa: Secondary Outcomes from the ACT 2 Randomized Controlled Trial

    by Carla J. Chibwesha, Nicholas S. Teodoro, Katie R. Mollan, Jessica R. Keys, Chuning Liu, Masangu Mulongo, Sibusisiwe Gumede, Tafadzwa Pasipamire, Mark Faesen, Lisa Rahangdale

    Objective: We report secondary histologic and high-risk HPV (hrHPV) outcomes from the Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living with HIV (ACT 2) Trial. Methods: We conducted a double-blind Phase 2b feasibility trial of loop electrosurgical excision procedure (LEEP) combined with adjuvant intravaginal 5-fluorouracil (5FU) cream. Women living with HIV (WLWH) and cervical intraepithelial neoplasia (CIN) 2/3 underwent LEEP and were randomly assigned (1:1) to receive 8 doses of 5FU or placebo cream. Our secondary outcomes were (a) regression of cervical disease and (b) clearance of hrHPV. Results: From March 2023 to January 2025, 180 participants underwent LEEP and were randomized to 5FU or placebo cream. Median age was 41 years (IǪR: 35-45), 29% had HPV16, 18% had HPV18/45; 99% of women were virologically suppressed (<200 copies/mL) and median CD4 count was 636 cells/uL (IǪR: 376-873). 172 participants (95.6%) completed follow-up. At week 24, 96.3% (78/81) in the 5FU group and 82.0% (73/89) in the placebo group regressed to CIN1 or normal histology (PD 14.3%, CI 5.3%, 23.3%). Among participants with positive LEEP margins at week 0, 88.0% (22/25) in the 5FU versus 61.3% (19/31) in the placebo group regressed to CIN1 or normal (PD 26.7%, CI 5.4%, 48.1%). Genotype-specific hrHPV clearance was similar in both groups (5FU: 58.0%, 40/69; Placebo: 53.8%, 43/80; PD 4.2%, CI −11.7%, 20.2%). Conclusion: Clinical outcomes from our Phase 2b trial demonstrates that intravaginal 5FU post-LEEP may be a beneficial adjuvant treatment for CIN2/3. Clinical Trial Registration: NCT05413811

  • Open Access

    Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among Women Living with HIV in South Africa: Primary Outcomes from the ACT 2 Randomized Trial

    by Nicholas S. Teodoro, Katie R. Mollan, Jessica R. Keys, Chuning Liu, Masangu Mulongo, Sibusisiwe Gumede, Tafadzwa Pasipamire, Mark Faesen, Melissa A. Mischell, Lisa Rahangdale, et al.

    Objective: Determine acceptability and feasibility of loop electrosurgical excision procedure (LEEP) combined with adjuvant intravaginal 5-fluorouracil (5FU) for treatment of cervical intraepithelial neoplasia grade 2/3 (CIN2/3) in women living with HIV (WLWH). Design: Double-blind, randomized, placebo-controlled Phase 2b feasibility trial. Setting: Public-sector hospital in Johannesburg, South Africa. Population: 180 WLWH aged 18+ years with CIN2/3 confirmed by LEEP and on antiretroviral therapy for ≥60 days. Methods: Participants underwent LEEP and were randomly assigned (1:1) to receive 8 doses of adjuvant 5FU or placebo cream every other week and followed for 24 weeks. Main Outcome Measures: The primary outcomes were acceptability and feasibility (adherence, retention, safety, tolerability). Results: Between March 2023 and January 2025, we randomized 180 WLWH. Median age was 41 years (interquartile range [IQR]: 35–45), median CD4+ count was 636 cells/mm³ (IQR: 376–873), and 98.9% were virologically suppressed. Acceptability (>94%) and adherence (>91%) were high and comparable between arms. Retention exceeded 92% in both arms, although Week 24 attendance was lower in the 5FU arm (92.2% vs. 98.9%, probability difference [PD] -6.7%, 95% confidence interval [CI] -14.4%, -0.5%). Safety events were mild, more common with 5FU, and primarily reported as Grade 1 or 2 cervical inflammation (49.2% vs. 26.7%, risk difference [RD] 22.5%, 95% CI 8.6%, 36.4%). One Grade 3 adverse event (an allergic reaction to 5FU) resulted in treatment discontinuation. Conclusions: LEEP plus adjuvant intravaginal 5FU is acceptable and feasible among WLWH in South Africa, supporting progression to a Phase 3 trial. Clinical Trial Registration: NCT05413811. Funding: United States National Institutes of Health (R01CA250850).


  • Open Access

    Group-based telehealth stress management—lifestyle interventions are feasible for patients with chronic liver disease

    by Donna M. Evon, Chuning Liu, Cathryn Rollason, Suzanne C. Lechner, Ashley R. Brown, Dawn S. Harrison, Paul Stewart, Donald E. Bailey, Leslie A. Morland, A. Sidney Barritt

    Background: Group-based, telehealth behavioral interventions may be efficient, effective, and acceptable treatment modalities for patients with chronic liver diseases; however, pilot feasibility and patient satisfaction data are needed to justify efficacy trials. Given the poor quality of life, symptoms, and health risk factors, patients with chronic hepatitis C–associated liver disease (HCV-LD) may benefit from psychosocial interventions. A pilot feasibility study of a videoconferencing-delivered cognitive behavioral coping skills intervention (“VC-CBCS”) was conducted to evaluate multiple indicators of feasibility, levels of patient satisfaction, and changes in patient-reported outcomes (PROs). Methods: We pilot tested a 14-week, 90-minute VC-CBCS intervention by conducting a small randomized controlled trial. Thirty-two adults with HCV-LD and high stress/symptom levels were randomized to the protocolized VC-CBCS intervention (n=24) or standard of care (n=8), in 4 waves of 7–9 participants in 2020–2021. Results: Based upon rates of approach to enrollment (60%), retention (84%), PRO data collection (99.4%), and session attendance (91%), a future efficacy trial appears highly feasible. Levels of participant satisfaction were encouraging for VC delivery, intervention content and structure, and group processes. Technological and behavioral issues were minor. Collection of in-home saliva testing was not feasible. Moderate to large pre–post-intervention effect sizes were observed for some mediators (perceived stress, coping, relaxation, self-efficacy, sleep hygiene), with some of these changes correlating with small to moderate improvements in mental health and symptoms (eg, depression, fatigue; effect size range: 0.23–0.47). No consistent patterns were evident between changes in eating and exercise behaviors and PROs. Conclusions: A group-based VC-CBCS intervention appears feasible and may address unmet psychosocial needs in patients living with chronic liver disease.


  • Implementation of 2HELPS2B Seizure Risk Score

    by Fazila Aseem, Emily Fink, Chuning Liu, John Whalen, Jessica Werdel, Parin Nanavati, Fei Zou, Angela Wabulya, Casey Olm-Shipman, Suzette Maria LaRoche, et al.

    Continuous EEG (cEEG) has become a standard for monitoring critically ill patients, but it is resource-intensive with limited availability. The 2HELP2B seizure risk score can help stratify seizure risk and aid in clinical decision making to optimize duration of monitoring. This study aimed to incorporate the 2HELPS2B score to inform cEEG duration and provide cost-effective care without compromising seizure detection. We conducted a quality improvement study that targeted clinical workflow and seizure risk stratification in the intensive care units of a tertiary academic hospital. The study included adult patients who underwent cEEG between June 2020 and December 2022 (n = 552), after excluding patients undergoing cEEG for management of status epilepticus, spell characterization, intracranial pressure monitoring, and post-cardiac arrest (n = 129). We performed a retrospective chart review to establish baseline cEEG volume, seizure incidence, and monitoring duration. We then introduced the 2HELPS2B risk score through multidisciplinary education and used published recommendations to suggest optimal cEEG duration. After the intervention, we analyzed the impact of integrating the 2HELPS2B score on cEEG duration and seizure detection rates. Of 552 patients, most were low risk (n = 311, 56.3%), followed by moderate risk (n = 189, 34.2%) and high risk (n = 52, 9.4%). Before the intervention, cEEG duration was similar for all risk groups. After implementation of the 2HELPSB score, there was a significant reduction in cEEG duration for low-risk and moderate-risk patients (low 36.3 vs 23.8 hours; p < 0.0001, moderate 36.5 vs 29.3 hours; p = 0.01) and no significant change for the high-risk group (41.3 vs 40.4 hours; p = 0.92). Seizure detection was low except for the high-risk group (1.3% vs 7.9% vs 39.1%). Reduction in cEEG duration after implementation of the 2HELPS2B score did not lead to a significant change in seizure detection (0.6% vs 9% vs 37.9%). Most critically ill patients had low or moderate seizure risk and, accordingly, a low incidence of seizures detected during cEEG. Implementing the 2HELPS2B seizure risk score allowed customization of cEEG duration for individual patients, applying the practice of precision medicine. This approach successfully improved cEEG utilization without compromising seizure detection. In conclusion, implementing seizure risk stratification can provide cost-effective monitoring and improve cEEG access.


  • Open Access

    Normal Saline vs Plasma-Lyte A Use Intra- and Post-Operatively in Adult Kidney Transplant Recipients

    by Kristen R Szempruch, Alec D Martschenko, Harendra Arora, Robert S Isaak, Ravindra Prasad, John L Schmitz, Chuning Liu, Fei Zou, Pablo Serrano Rodriguez

    Fluid management intra- and post-operatively for kidney transplant recipients (KTR) is essential to maintain adequate perfusion to the kidney. 0.9% normal saline (NS) is commonly used, but it can cause hyperchloremic metabolic acidosis, which may result in hyperkalemia and lead to delayed graft function (DGF). Plasma-Lyte A (PA) is an alternative option that has a lower amount of chloride and a neutral pH, which may offset the risk of hyperkalemia. The aim of this study is to determine the incidence of DGF in KTRs comparing NS vs PA use intra- and initially post-operatively. This single-center, retrospective cohort study in adult KTRs from January 1, 2016 to February 1, 2021 consisted of two cohorts, those receiving NS vs PA. Multi-organ transplant recipients were excluded. The primary outcome was the incidence of DGF. A total of 244 KTRs in the NS group and 263 KTRs in the PA group were included. There was no significant difference in incidence of DGF between the groups, (NS 23.4% vs PA 25.9%, p = 0.537). The logistic regression for only deceased donors were not significantly different (OR 1.369 (0.819-2.288). There was no difference in the incidence of DGF when comparing NS vs PA.

  • Open Access

    The union of intervals in constructive mathematics

    by Chuning Liu, Wenqi Shen

    Constructive Real Numbers (CRNs) are the concept of real numbers used in Constructive Mathematics, where the objects are thought of as being generated by a computer program. This paper focuses on the property of unions in the constructive end, which means that we study the union of intervals from the viewpoint of Constructive Mathematics. In the end, we prove that for t < u ≤ v < w (t, u, v, w are CRN), then it is always true that [t, v] ∪ [u, w] ⊂ [t, w] but generally it is not true that [t, w] ⊂ [t, v] ∪ [u, w]. However, for t < u < v < w(t, u, v, w are CRN), it is always true that [t, w] = [t, v] ∪ [u, w].